Paul Loren Swiecicki, MD

Paul Loren Swiecicki, MD
Specialty: Medical Oncology, Internal Medicine
Title: Clinical Associate Professor
4.9/5
See All Ratings

Accepts most insurance plans

To request an appointment call

734-936-8051
Paul Loren Swiecicki, MD
Paul Loren Swiecicki, MD
Medical Oncology
  • Areas of Practice
  • Locations
  • Insurance
  • Education & Training
  • Research Overview
  • Patient Ratings & Comments

  • Manage Your Profile

    • Areas of Practice
    head and neck cancer, salivary gland cancer, adenoid cystic carcinoma, phase 1 clinical trials, oropharyngeal cancer, laryngeal cancer, oral cavity cancer, cutaneous squamous cell carcinoma

    Locations
    • Otolaryngology Clinic | Taubman Center 1500 E Medical Center Dr
      Floor 1 Reception A
      Ann Arbor, MI 48109-5312       Get Directions
    • Head and Neck Oncology Clinic | Rogel Cancer Center 1500 E Medical Center Dr
      Floor B1 Reception E
      Ann Arbor, MI 48109-5912       Get Directions

    Insurance Accepted

    University of Michigan Health participates with most health insurance plans.

    See our insurance details

    Education & Training

    Medical School or Training
    Michigan State University-College of Human Medicine, 2011

    Residency
    Mayo Clinic, Internal Medicine, 2014

    Fellowships
    University of Michigan Health System, Internal Medicine Hematology Oncology, 2017

    Board Certifications
    Medical Oncology

    Professional Organizations
    American College of Physicians 
    American Medical Association
    American Society of Clinical Oncology 
    American Society of Hematology

    Research Overview
    My research focuses on development of novel therapeutics for advanced head and neck cancer, advancing new biomarkers which could help guide patient care/management, identifying treatments for metastatic salivary gland cancers, and conducting early phase clinical trials.

    Patient Ratings & Comments

    Visit our Physician Ratings & Comments page to learn more about how patient ratings are collected, calculated, and updated to help you make an informed decision when choosing the right physician for your care.

    Patient Ratings

    256 Patient Ratings

    Patient Comments

    May 13, 2026 - "Dr. Swiecicki seemed annoyed I wasn't sold on [...]. I would prefer facts instead of metaphors for what is actually happening with therapies or procedures because I love words and science. He did not go over my [...] with me, and neither did [...], which I think is odd. There's a lot of unexplained [...]. He talked about some side effects of [...] and let me know it would continue long after [...]"

    May 8, 2026 - "Dr Paul Swiecicki is one fantastic doctor. He listens and is extremely focused on my treatment plan. Always upbeat. Awesome doctor."

    April 16, 2026 - "Dr. Paul Swiecicki has been my life saver. Literally! His professional and personal concern for my well-being has been second to none!!!! Thank you, Dr. Paul [...]!!"

    December 3, 2025 - "Dr. Swiecicki [...] takes time to listen, explain and answer ALL of my questions. His bedside manner is top notch and his knowledge if first rate. I felt very confident in the care I received."

    November 1, 2025 - "Dr Swiecicki has given me excellent care and advice thru this journey"

    October 15, 2025 - "Dr. Paul Swiecicki has treated me with respect and professionalism since my first meeting with him [...]. I credit Dr. Swiecicki and [...] with no less than saving my life!!"

    October 11, 2025 - "Dr Swiecicki took the time to understand our concerns and answered ALL questions for ALL family members that were there (there were three of us). We left with hope that my health issues could be solved."

    August 27, 2025 - "Love Dr. Swiecicki, he is the Best!!"

    Featured News & Stories

         woman touching her neck in robe at home
    Health Lab

    Phase 1 trial of alrizomadlin shows promise in targeting metastatic salivary gland cancers

    University of Michigan researchers, in partnership with Ascentage Pharma, developed a drug known as alrizomadlin, or APG-115, to target metastatic salivary gland cancers.